By Anthony O. Goriainoff

 

Hutchmed (China) said Friday that its fruquintinib cancer treatment has been granted a priority review of the New Drug Application by the U.S. Food and Drug Administration.

The London-listed biopharmaceutical company said that if approved fruquintinib will be the first and only highly selective inhibitor of all three vascular endothelial growth factor receptors approved in the U.S. for previously treated metastatic colorectal cancer.

Hutchmed said the FDA plans to complete the review process by Nov. 30.

Fruquintinib is approved in China as a treatment for refractory metastatic colorectal cancer, the company said.

"Today's acceptance marks a significant advancement towards the goal of providing patients with previously treated metastatic colorectal cancer a much-needed therapeutic option, given the limited treatment options currently available to patients," the company said.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

May 26, 2023 02:51 ET (06:51 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more HUTCHMED China Charts.
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more HUTCHMED China Charts.